Sintilimab and Nab-paclitaxel in Second-line Treatment of Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma
To evaluate the efficacy and safety of Sintilimab (PD-1 inhibitor) and nab-paclitaxel in second line treatment of advanced gastric and gastro-esophageal junction adenocarcinoma. This is a prospective, multi-centers, single arm phase II trial with primary objective overall response rate and second objective of safety and other efficacy endpoints.
Advanced Gastric and Gastro-esophageal Junction Adenocarcinoma
DRUG: sintilimab|DRUG: nab-paclitaxel
ORR, up to two years
DCR, disease control rate, up to three years|DOR, duration of response, up to three years|AE, treatment related adverse event, from first dose to 90days of last dose|PFS, progression free survival, up to three years|OS, overall survival, up to three years
To evaluate the efficacy and safety of Sintilimab (PD-1 inhibitor) and nab-paclitaxel in second line treatment of advanced gastric and gastro-esophageal junction adenocarcinoma. This is a prospective, multi-centers, single arm phase II trial with primary objective overall response rate and second objective of safety and other efficacy endpoints.